A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events
Prescribing Information [External link]
Download this slide deck for information on the MOA of KEYTRUDA and the management of immune-mediated adverse events.
Please consult the Summary of Product Characteristics and risk minimisation material for further information to minimise the risks associated with the use of this medicine before making any prescribing decisions.
More information about KEYTRUDA® (pembrolizumab):
Related content
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
